Annuncio • Mar 30

+ 1 more update

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business. The vaccine portfolio seeks to address infectious diseases that cause considerable health burdens and includes 28 vaccines addressing respiratory, latent and other pathogens. Latent and Other Vaccine Portfolio: Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms. Latent viruses can reactivate and cause clinical symptoms as a person ages, during times of stress or when immunity is compromised. The capacity for latency is a de?ning feature of members of the Herpesviridae family, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV) and Varicella-Zoster virus (VZV). Cytomegalovirus (CMV): CMV is the most common infectious cause of birth defects in the U.S. and is responsible for several billion dollars in annual healthcare costs. One in 200 babies in the U.S. are born with a congenital CMV infection, and of those affected, one in five will have severe, life-altering health problems. Possible short- and long-term sequelae of CMV infection include microcephaly, chorioretinitis, seizures, sensorineural hearing loss, cognitive impairment and cerebral palsy. There is currently no approved vaccine to prevent congenital CMV. CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age. The trial is a randomized, observer-blind, placebo-controlled study designed to evaluate the efficacy, safety and immunogenicity of mRNA-1647. The trial is fully enrolled with approximately 7,300 participants from 290 clinical sites globally. To date, 50 primary infection cases have accrued and are undergoing confirmation. The first interim analysis for the evaluation of vaccine efficacy, which will be triggered when both 81 confirmed per-protocol cases and 12 median months of safety follow-up have occurred, is expected as early as the end of 2024. Moderna's CMV vaccine candidate mRNA-1647 has advanced to indication expansion studies in adolescents 9 to 15 years of age and adult transplant patients, both of which have begun enrollment. Epstein-Barr virus (EBV): EBV is a major cause of infectious mononucleosis (IM) in the U.S., accounting for more than 90% of IM cases annually. Importantly, EBV and IM are associated with a higher lifetime risk of more serious sequelae including certain cancers such as gastric carcinoma, nasopharyngeal carcinoma and multiple types of lymphoma. The lifetime risk of developing multiple sclerosis (MS) is increased by 32-fold after EBV infection. There is currently no approved vaccine to prevent EBV. Moderna's EBV vaccine candidates are designed to tackle multiple EBV-associated conditions, including prevention of IM (mRNA-1189) and MS and post-transplant lymphoproliferative disorder, a subcategory of lymphoma in solid organ transplant patients (mRNA-1195). The Phase 1 trial for mRNA-1189 was designed to test the safety, reactogenicity and immunogenicity of four different dose levels in participants 12 to 30 years of age in the U.S. The randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. The Company is advancing mRNA-1189 toward a pivotal Phase 3 trial. The Phase 1 trial for mRNA-1195 was designed to test the safety, reactogenicity and immunogenicity of two drug products at four different dose levels in healthy EBV seropositive participants 18 to 55 years of age in the U.S. The randomized, observer-blind, placebo-controlled study is fully enrolled. Herpes simplex virus (HSV): Herpes simplex virus type 2 (HSV-2) infects approximately 13% of adults globally and is the primary cause of genital herpes. There are an estimated four billion people globally infected with HSV, of which 491 million cases are HSV-2. Recurrent genital herpes causes a reduction in quality of life, which antivirals (current standard of care) only partially restore. Moderna expects that if an HSV vaccine candidate could deliver similar efficacy as a suppressive antiviral treatment, compliance with recommended therapy and associated quality of life would improve. The first in human, fully enrolled Phase 1/2 trial of mRNA-1608 is designed to test safety and immunogenicity and to establish a proof-of-concept of clinical benefit in adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The randomized 1:1:1:1, observer-blind, controlled study is fully enrolled with 300 participants in the U.S. Varicella-Zoster virus (VZV): Herpes zoster, also known as shingles, is caused by reactivation of latent VZV, the same virus that causes chickenpox. Declining immunity in older adults decreases immunity against VZV, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Herpes Zoster occurs in one out of three adults in the U.S. in their lifetime and the incidence increases at 50 years of age. Moderna's VZV vaccine candidate mRNA-1468 has initial data available from a Phase 1/2 trial, which was designed to test safety and immunogenicity in healthy adults 50 years of age and older in the U.S. The randomized 1:1:1:1:1, observer-blind, active-controlled study of mRNA-1468 elicited strong antigen-specific T cell responses at one month after the second dose and was generally well tolerated. Additional results from the ongoing Phase 1/2 study will be available later this year, including persistence data. The Company is planning for a pivotal Phase 3 trial. Norovirus: Enteric viruses, including norovirus, are a leading cause of diarrheal diseases, resulting in significant morbidity and mortality worldwide, particularly among young children and older adults. Norovirus is highly contagious and a leading cause of diarrheal disease globally, associated with 18% of all acute gastroenteritis (AGE), resulting in approximately 200,000 deaths per year and substantial healthcare costs. The randomized, observer-blind, placebo-controlled Phase 1 trial was designed to evaluate the safety, reactogenicity and immunogenicity of trivalent?(mRNA-1403)?and pentavalent?(mRNA-1405) norovirus vaccine candidates in 664 participants 18 to 49 years of age and 60 to 80 years of age in the U.S. An interim analysis showed that a single dose of mRNA-1403 elicited a robust immune response across all dose levels evaluated with a clinically acceptable reactogenicity and safety profile. The Company is advancing mRNA-1403 toward a pivotal Phase 3 trial.

Biotechs Crescita del settore	12.91%
Tasso di crescita dei ricavi	-40.03%
Rendimento del capitale proprio	-46.61%
Margine netto	-141.43%
Ultimo aggiornamento sugli utili	30 Jun 2026

Data	Ricavi	Utili	Spese G+A
30 Jun 26	2,228	-3,151	965
31 Mar 26	2,225	-3,194	979
31 Dec 25	1,944	-2,822	1,018
30 Sep 25	2,232	-3,116	1,061
30 Jun 25	3,078	-2,903	1,074
31 Mar 25	3,177	-3,357	1,112
31 Dec 24	3,236	-3,561	1,174
30 Sep 24	5,081	-2,224	1,293
30 Jun 24	5,050	-5,867	1,454
31 Mar 24	5,153	-5,968	1,518
31 Dec 23	6,848	-4,714	1,549
30 Sep 23	9,121	-3,466	1,454
30 Jun 23	10,654	1,207	1,290
31 Mar 23	15,059	4,784	1,169
31 Dec 22	19,263	8,362	1,132
30 Sep 22	21,390	11,765	958
30 Jun 22	22,995	14,055	848
31 Mar 22	22,600	14,638	758
31 Dec 21	18,471	12,202	567
30 Sep 21	11,831	7,061	445
30 Jun 21	7,019	3,495	325
31 Mar 21	2,732	598	241
31 Dec 20	803	-747	188
30 Sep 20	246	-597	135
30 Jun 20	106	-488	115
31 Mar 20	52	-505	106
31 Dec 19	60	-514	110
30 Sep 19	82	-535	122
30 Jun 19	106	-499	112
31 Mar 19	122	-459	105
31 Dec 18	135	-402	94
30 Sep 18	192	-299	72
30 Jun 18	192	-280	70
31 Mar 18	199	-266	65
31 Dec 17	206	-270	65
31 Dec 16	108	-230	57

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/09/14 20:12
Prezzo dell'azione a fine giornata	2026/09/14 00:00
Utili	2026/06/30
Utili annuali	2025/12/31

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
null null	Argus Research Company
Huidong Wang	Barclays
"Eliana Merle	Barclays

Moderna Performance degli utili passati

Criteri Il passato verificati 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2026 earnings released: US$1.97 loss per share (vs US$2.13 loss in 2Q 2025)

First quarter 2026 earnings released: US$3.40 loss per share (vs US$2.52 loss in 1Q 2025)

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

Full year 2025 earnings released: US$7.25 loss per share (vs US$9.27 loss in FY 2024)

Moderna, Inc. to Report Q4, 2025 Results on Feb 13, 2026

Third quarter 2025 earnings released: US$0.51 loss per share (vs US$0.034 profit in 3Q 2024)

Recent updates

Moderna Receives Fda Approval for Mflusiva, the First Mrna Influenza Vaccine for Adults 50 and Older

Merck & Co., Inc. And Moderna, Inc. Announce Phase 3 INTerpath-001 Trial Of Intismeran Autogene Plus KEYTRUDA Met Endpoints Of Recurrence-Free Survival And Distant Metastasis-Free Survival In Patients With Completely Resected Stage IIB-IV Melanoma

Health Canada Authorizes Moderna To Move Forward With Phase I Clinical Trial For Candidate Mrna Vaccine For Ebola Disease Caused By The Bundibugyo Virus

Second quarter 2026 earnings released: US$1.97 loss per share (vs US$2.13 loss in 2Q 2025)

Moderna, Inc. Announces Board and Committee Changes, Effective July 8, 2026

Moderna Receives Unanimous FDA Panel Recommendation for mRNA-Based Influenza Vaccine for Adults 50 and Older

Moderna Plans Multiple Product Launches in 2027 and 2028

First quarter 2026 earnings released: US$3.40 loss per share (vs US$2.52 loss in 1Q 2025)

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

Moderna, Inc., Annual General Meeting, May 06, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement with Moderna

Now 21% undervalued

Full year 2025 earnings released: US$7.25 loss per share (vs US$9.27 loss in FY 2024)

Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010

Arbutus Biopharma Corporation Announces Court Ruling on Patent Infringement Dispute over Lipid Nanoparticle Vaccine Technology

Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026

Moderna, Inc. to Report Q4, 2025 Results on Feb 13, 2026

Moderna, Inc. Lowers Earnings Guidance for Full Year 2025

Third quarter 2025 earnings released: US$0.51 loss per share (vs US$0.034 profit in 3Q 2024)

Moderna, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Moderna, Inc.(NasdaqGS:MRNA) dropped from FTSE All-World Index (USD)

Second quarter 2025 earnings released: US$2.13 loss per share (vs US$3.33 loss in 2Q 2024)

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Value Index

he START Center for Cancer Research Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, A Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

First quarter 2025 earnings released: US$2.52 loss per share (vs US$3.08 loss in 1Q 2024)

Moderna, Inc. to Report Q1, 2025 Results on May 01, 2025

CEO & Director recently bought Mex$102m worth of stock

Genevant Sciences and Arbutus Biopharma Corporation Initiate International Patent Infringement Enforcement Actions Against Moderna

Moderna, Inc., Annual General Meeting, Apr 30, 2025

Moderna, Inc. Re-Iterates Earnings Guidance for the Full Year 2025

Full year 2024 earnings released: US$9.27 loss per share (vs US$12.34 loss in FY 2023)

Moderna, Inc. to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2024 earnings released: EPS: US$0.034 (vs US$9.53 loss in 3Q 2023)

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Now 27% undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold Mex$40m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Moderna, Inc. Provides Sales Guidance for the Year 2023